Short answer · Medically reviewed summary · Last updated: 2026-05-08
TL;DR: Pallister-Killian Syndrome (PKS), also known as Tetrasomy 12p, is an ultra-rare chromosomal disorder with an estimated prevalence of approximately 1 in 20,000 to 1 in 25,000 live births. Due to the high rate of diagnostic challenges and mosaicism, the true global prevalence remains difficult to determine accurately. Is Pallister-Killian Syndrome considered a rare condition? Yes, Pallister-Killian Syndrome is classified as an ultra-rare genetic condition.
What is the prevalence of Pallister-Killian Syndrome / Tetrasomy 12p?
Prevalence of Pallister-Killian Syndrome / Tetrasomy 12p: how many people are affected worldwide, differences by sex and region, with sources.
TL;DR: Pallister-Killian Syndrome (PKS), also known as Tetrasomy 12p, is an ultra-rare chromosomal disorder with an estimated prevalence of approximately 1 in 20,000 to 1 in 25,000 live births. Due to the high rate of diagnostic challenges and mosaicism, the true global prevalence remains difficult to determine accurately.
Is Pallister-Killian Syndrome considered a rare condition?
Yes, Pallister-Killian Syndrome is classified as an ultra-rare genetic condition. Because the extra genetic material (the isochromosome 12p) is often present in a mosaic pattern—meaning it is only found in some of the body’s cells—it can be missed during standard genetic testing. This leads to significant underdiagnosis, as many individuals may remain undiagnosed or misdiagnosed for years.
What are the challenges in identifying the true prevalence of Tetrasomy 12p?
The primary hurdle in tracking Pallister-Killian Syndrome is the tissue-specific nature of the mosaicism. The abnormal cell line often disappears from blood samples as a person ages, meaning that skin biopsies or other tissue samples are required for an accurate diagnosis. Consequently, clinical registry data often underestimates the actual number of people living with Tetrasomy 12p.
How does the condition affect different populations?
Current clinical literature indicates the following regarding the epidemiology of Pallister-Killian Syndrome:
- Gender Distribution: There is no evidence suggesting a predilection for one sex over the other; Pallister-Killian Syndrome affects males and females equally.
- Age of Onset: This is a congenital condition present from conception; however, diagnosis often occurs in early childhood when developmental delays become apparent.
- Geographic/Ethnic Variations: No specific geographic or ethnic clusters have been identified, indicating that Tetrasomy 12p occurs sporadically worldwide.
What does the DiseaseMaps community experience show?
While formal medical literature provides the foundational statistics, the DiseaseMaps.org community offers a vital real-world perspective. Currently, 9 people with Pallister-Killian Syndrome have joined our community, helping researchers and families better understand the lived experience of this condition beyond the clinical numbers.
Next steps
- Consult with a clinical geneticist to discuss whether skin fibroblast testing is appropriate if blood-based genetic tests were inconclusive.
- Connect with the DiseaseMaps.org community to share experiences with other families affected by Pallister-Killian Syndrome.
- Register with disease-specific patient advocacy groups to stay informed about potential clinical trials and research updates.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare professional regarding any medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Pallister-Killian syndrome.
- Orphanet: Pallister-Killian syndrome (ORPHA:2836).
- OMIM (Online Mendelian Inheritance in Man): Tetrasomy 12p mosaicism (#601803).
- Pallister-Killian Syndrome Foundation (PKS Kids).
